DICE Therapeutics
Tim Church has a diverse and extensive work experience in the field of medicinal chemistry. Tim started their career in 1995 at Arris Pharmaceuticals as a Research Associate II, where they conducted research in medicinal chemistry, performed chemistry work, purification, and contributed to patent publication. After that, they worked at Theravance as a Scientist in Medicinal Chemistry for more than a decade. Tim then joined STATegics, Inc. as a Scientist in Medicinal Chemistry before briefly working at Achaogen as a Medicinal Chemistry Scientist in a contract position. Tim continued their career at STATegics, Inc. as a Scientist in Medicinal Chemistry for one year. In 2010, they joined Oligasis as a Scientist in Organic Chemistry. From there, they joined Novartis Institutes for BioMedical Research (NIBR) as a Scientist II in Medicinal Chemistry. Currently, Tim is working at DiCE Molecules, where they started as a Scientist II in Medicinal Chemistry and was later promoted to Associate Director of Medicinal Chemistry.
Tim Church completed their Bachelor of Science degree in Chemistry from Alma College in the years 1988 to 1992. Tim then pursued further education and obtained a Master of Science degree in Organic Chemistry from the University of Notre Dame from 1992 to 1995.
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.